Quick Overview: Krishna V. Komanduri, MD; David Maloney, MD, PhD; and Stephen J. Schuster, MD, describe the rationale for Website: Twitter: Facebook: LinkedIn: ... Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, ...
Bcma Targeted Car T Cell - Detailed Overview & Context
Krishna V. Komanduri, MD; David Maloney, MD, PhD; and Stephen J. Schuster, MD, describe the rationale for Website: Twitter: Facebook: LinkedIn: ... Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, ... Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the promising results of anti- Elisabet Manasanch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I first-in-human ... Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, explains where
Parameswaran Hari, MD, MRCP, projects how B-cell maturation antigen ( Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the Alfred Garfall, MD, MS University of Pennsylvania, Pennsylvania, PA, discusses the latest results looking at anti- Idecabtagene vicleucel (ide-cel; bb2121), a Multiple myeloma (MM) is at the forefront of immunotherapeutic developments, including A. Keith Stewart, MB, ChB; Edward A. Stadtmauer, MD; Ajai Chari, MD; Thomas Martin, MD; and Amrita Krishnan, MD, review the ...
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives a summary of his talk on B- Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, discusses the downregulation of B- Amrita Krishnan, MD, City of Hope, Duarte, CA, briefly comments on how Future relapsed-refractory multiple myeloma treatment strategies with Laurent Garderet, MD, from Hopital Saint-Antoine, Paris, France, talks
